Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure

对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制

基本信息

  • 批准号:
    10320929
  • 负责人:
  • 金额:
    $ 34.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary Overdose of acetaminophen (APAP), the popular analgesic and antipyretic agent, is the most common cause of acute liver failure (ALF) in the Western world. Treatment options for APAP-induced ALF are extremely limited. Most ALF patients are treated with N-acetyl cystein, a precursor of glutathione, which works only if delivered within hours after APAP overdose. The only other therapy is liver transplantation, which is complicated by scarcity of donor organs, life long immunosuppressant use and exorbitant cost. There is a critical need to develop novel therapies for APAP-induced ALF. Recent studies using animal models and patient samples have demonstrated that timely stimulation of innate liver regeneration is associated with better outcomes including transplant free survival in APAP-induced ALF. These studies indicate that without proper liver regeneration, APAP-induced acute liver injury can develop into ALF and result in death. These studies underscore the therapeutic potential of liver regeneration following APAP-induced ALF. However, the mechanisms of liver regeneration after APAP overdose are not completely known. In the previous cycle of this grant, we investigated the role of canonical Wnt--catenin signaling in liver regeneration after APAP overdose. Interestingly, our preliminary studies have uncovered a novel and paradoxical role for Hippo Kinase pathway and its downstream regulator yes associated protein (Yap) in pathogenesis of APAP-induced ALF. Our studies, performed using hepatocyte specific Yap knockout (Yap-KO) mice, indicate that Yap activation after APAP overdose is associated with delayed regeneration after APAP overdose. Deletion of Yap resulted in enhanced liver regeneration leading to faster recovery after APAP overdose. Mechanistically, deletion of Yap in hepatocytes resulted in faster activation of -catenin, which stimulated the faster liver regeneration after APAP administration. Furthermore, we observed a faster and augmented pro-regenerative inflammatory response driven by higher expression of serum amyloid A and CXCL1, both -catenin targets in hepatocytes, in the Yap- KO mice. Finally, our preliminary studies indicate that Yap and its target gene connective tissue growth factor (CTGF) could be used as prognostic markers in APAP-induced ALF. These studies will explore an unconventional and novel role of Yap in drug induced acute liver failure and subsequent liver regeneration. Successful completion of these studies will have substantial impact on clinical management of APAP overdose because they will identify Yap as a new target for regenerative therapies for APAP-induced ALF patients.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Udayan Apte其他文献

Udayan Apte的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Udayan Apte', 18)}}的其他基金

Kansas Center for Metabolism and Obesity REsearch (KC-MORE) - Cells, Tissues, Bioanalysis and Biostatistics Core
堪萨斯代谢和肥胖研究中心 (KC-MORE) - 细胞、组织、生物分析和生物统计学核心
  • 批准号:
    10598036
  • 财政年份:
    2022
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    9886668
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    9040935
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    8826109
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    8482328
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    8619622
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    9249528
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    10077553
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure
对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制
  • 批准号:
    10538643
  • 财政年份:
    2013
  • 资助金额:
    $ 34.43万
  • 项目类别:
ROLE OF HNF4ALPHA IN REGULATION OF HEPATOCYTE PROLIFERATION
HNF4α 在肝细胞增殖调节中的作用
  • 批准号:
    8360786
  • 财政年份:
    2011
  • 资助金额:
    $ 34.43万
  • 项目类别:

相似海外基金

Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
衰老肝细胞介导急性肝衰竭中免疫细胞的重编程
  • 批准号:
    10679938
  • 财政年份:
    2023
  • 资助金额:
    $ 34.43万
  • 项目类别:
Hepatocytes Encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute Liver failure in Paediatric patients (HELP)
将间充质基质细胞封装在藻酸盐微珠中的肝细胞用于治疗儿科患者的急性肝衰竭(HELP)
  • 批准号:
    MR/V038583/1
  • 财政年份:
    2022
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Research Grant
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
  • 批准号:
    10421290
  • 财政年份:
    2021
  • 资助金额:
    $ 34.43万
  • 项目类别:
Development of the innovative treatment using self iPS cell for acute liver failure
开发利用自身 iPS 细胞治疗急性肝衰竭的创新疗法
  • 批准号:
    21K08685
  • 财政年份:
    2021
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
  • 批准号:
    10180251
  • 财政年份:
    2021
  • 资助金额:
    $ 34.43万
  • 项目类别:
Therapeutic effect of plasmacytoid dendritic cells transplantation for acute liver failure
浆细胞样树突状细胞移植治疗急性肝衰竭的疗效
  • 批准号:
    20K21607
  • 财政年份:
    2020
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Macrophage Therapy for Acute Liver Failure
巨噬细胞治疗急性肝衰竭
  • 批准号:
    MR/T044802/1
  • 财政年份:
    2020
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Research Grant
Investigation of an optimal environment for the proliferation of mature hepatocytes toward the rescue of acute liver failure patients
研究成熟肝细胞增殖的最佳环境以挽救急性肝衰竭患者
  • 批准号:
    19K08475
  • 财政年份:
    2019
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure (PALF) TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
小儿急性肝衰竭 (PALF) 免疫介导病理生理学治疗 (TRIUMPH)
  • 批准号:
    9789253
  • 财政年份:
    2018
  • 资助金额:
    $ 34.43万
  • 项目类别:
Cryopreservation of hiPS-derivd hepatic progenitor cells and application to acute liver failure treatment
hiPS源性肝祖细胞的冷冻保存及其在急性肝衰竭治疗中的应用
  • 批准号:
    18K08662
  • 财政年份:
    2018
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了